[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Oui Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":86},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100617243","phase-2-determining-the-potential-for-efficacy-of-otx-601-in-reducing-ptsd-symptoms-100617243",false,"NCT07316088","Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms","Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms in a Randomized Controlled Trial (RCT)","Inclusion Criteria:\n\n* Posttraumatic stress disorder (PTSD) diagnosis\n* Anxiety Sensitivity Index 3 (ASI-3) scores above 24\n* PTSD Checklist for DSM-V (PCL-5) scores above 30\n* Understands and speaks English\n* Access to a smartphone that is connected to the internet\n\nExclusion Criteria:\n\n* Score of 24 or lower on the ASI-3\n* Score of 30 and below on the PCL-5\n* No PTSD diagnosis\n* Active psychosis\n* Acute intoxication during study baseline\n* Enrolled in another treatment research study\n* Medical illness that would prevent the completion of interoceptive exposure exercises","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.",[26,27],"PTSD","Post Traumatic Stress Disorder",[26],"RECRUITING","2025-12-31",{"date":32,"type":33},"2026-01-05","ACTUAL",{"date":35,"type":33},"2025-12-09",{"date":37,"type":20},"2026-07-31",{"name":39,"class":40},"Oui Therapeutics, Inc.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":24,"conditions":51,"keywords":52,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100582833","phase-1-feasibility-of-a-digital-therapeutic-for-adults-with-posttraumatic-stress-disorder-ptsd-100582833","NCT06868446","Feasibility of a Digital Therapeutic for Adults With Posttraumatic Stress Disorder (PTSD)","Dosage, Feasibility, Acceptability and Usability of OTX-601",{"count":19,"type":20},[50],"PHASE1",[26,27],[26],"NOT_YET_RECRUITING","2025-06-16",{"date":56,"type":33},"2025-06-19",{"date":58,"type":20},"2025-06-30",{"date":60,"type":20},"2026-01-30",{"name":39,"class":40},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100550979","feasibility-of-a-digital-therapeutic-for-adults-with-binge-eating-and-obesity-100550979","NCT06454123","Feasibility of a Digital Therapeutic for Adults With Binge Eating and Obesity","A Feasibility Study of a Digital Therapeutic for Adults With Recurrent Binge Eating and Obesity","Inclusion Criteria:\n\n1. English speaking male or female patients, 18-70 years\n2. Patients with recurrent binge eating (≥12 episodes in 3 months) and obesity (BMI ≥30)\n3. Understand written and spoken English\n4. Own an iPhone with iOS 11 or higher, or Android with OS 8.1 or higher\n5. Willing and able to complete enrollment procedures\n6. Able to understand the nature of the study and provide written informed consent\n\nExclusion Criteria:\n\n1. Patients with active psychosis\n2. Patients who are acutely intoxicated at the time of enrollment\n3. Currently enrolled in other treatment studies for the symptoms and behaviors targeted\n4. Patients who are cognitively impaired\n5. Patients who, in the judgment of the investigator, would have an unfavorable risk\u002Fbenefit profile with respect to the digital therapeutic","70 Years",{"count":71,"type":20},30,[73],"NA","The primary objective of this study is to test the feasibility of a digital therapeutic to address comorbid binge eating and obesity in adults.",[76,77],"Binge Eating","Obesity","2024-06-06",{"date":80,"type":33},"2024-06-12",{"date":82,"type":20},"2024-09",{"date":84,"type":20},"2025-06",{"name":39,"class":40},""]